-
公开(公告)号:EP3705145B1
公开(公告)日:2024-10-30
申请号:EP17931049.5
申请日:2017-12-11
发明人: PENG, Chun , WANG, Chaofu
-
公开(公告)号:EP4415776A1
公开(公告)日:2024-08-21
申请号:EP22881720.1
申请日:2022-10-12
发明人: ELIAZ, Isaac
CPC分类号: A61M1/3496 , A61M1/3679 , A61M1/3486 , A61M1/3472 , A61M1/3687
-
公开(公告)号:EP4321215A3
公开(公告)日:2024-04-17
申请号:EP23199293.4
申请日:2017-06-22
申请人: Hemanext Inc.
IPC分类号: A61M1/36 , A61M1/38 , A61K35/14 , A61P7/08 , A61P1/04 , A61P3/10 , A61P7/00 , A61P9/00 , A61P11/00 , A61P17/00 , A61P19/00 , A61P29/00 , A61P19/02
CPC分类号: A61M1/36 , A61M1/38 , A61K35/14 , A61P1/04 , A61P11/00 , A61P17/00 , A61P19/02 , A61P29/00 , A61P3/10 , A61P7/00 , A61P7/08 , A61P9/00
摘要: Method for transfusion medicine to reduce adverse events in transfusion patient populations based on underlying patient physiology.
-
公开(公告)号:EP3548108B1
公开(公告)日:2024-01-31
申请号:EP17829769.3
申请日:2017-12-04
-
5.
公开(公告)号:EP3741404B1
公开(公告)日:2023-08-30
申请号:EP20175596.4
申请日:2020-05-20
-
公开(公告)号:EP3954407B1
公开(公告)日:2023-07-12
申请号:EP21198088.3
申请日:2019-05-21
-
公开(公告)号:EP4186540A1
公开(公告)日:2023-05-31
申请号:EP23152881.1
申请日:2019-05-21
申请人: Fenwal, Inc.
摘要: A plasmapheresis system and a method for operating a plasmapheresis system are provided by which the volume/weight of anticoagulated plasma that is collected is optimized. In one example, a nomogram is provided that utilizes the donor's hematocrit to calculate the volume/weight of raw plasma within a plasma product having the maximum volume permitted by the FDA nomogram. In a plasmapheresis procedure having multiple collection phases followed by a reinfusion cycle in which concentrated red blood cells are returned to the donor, the volume of plasma product to be collected is calculated prior to the start of each collection cycle to account for the donor's increasing hematocrit, thus resulting in a greater total volume of plasma product to be collected during the plasmapheresis procedure.
-
公开(公告)号:EP4183432A1
公开(公告)日:2023-05-24
申请号:EP20949945.8
申请日:2020-08-27
发明人: LI, Xianghai
摘要: Disclosed in the present application are a fluid treatment method, a fluid treatment device, a circulating separation device, a circulating treatment system, medical equipment, and a computer-readable storage medium. The fluid treatment method traps target materials in a fluid by means of an enrichment pipeline and a first separation module and cyclically enriches the target materials in the enrichment pipeline, and in this cyclic enrichment mode, the flow rates of the fluid at a fluid inlet and a fluid outlet in the enrichment pipeline are equal so as to dynamically balance the total amount of the fluid in the enrichment pipeline. Thus, the fluid treatment method of the present application is sustainable in treatment, and can collect some components in the fluid, that is, target materials. The fluid drained out of a first drainage port of the enrichment pipeline can be connected to a treatment module or returned to the original system. This method effectively avoids the continuous loss of beneficial components when harmful components are separated during component separation or exchange of the fluid through membrane separation.
-
公开(公告)号:EP3399986B1
公开(公告)日:2023-02-22
申请号:EP17704333.8
申请日:2017-01-06
发明人: WEINER, Elan , GREENMAN, William
-
10.
公开(公告)号:EP4129359A1
公开(公告)日:2023-02-08
申请号:EP22189034.6
申请日:2022-08-05
申请人: Fenwal, Inc.
发明人: MIN, Kyungyoon
摘要: Systems and methods are provided for separating platelets from blood. Prior to blood separation, a volume of blood to be processed, a volume of platelets to be collected, and/or a time required to complete blood draw from a source during a blood separation procedure is determined. Based on that determination, a procedure setpoint is calculated from the completion of the blood draw. Blood is subsequently drawn from a source into a separator in which the blood is separated into a mononuclear cell-containing fraction and a platelet-containing fraction. At least a portion of the platelet-containing fraction is conveyed from the separator, while the volume of the mononuclear cell-containing fraction in the separator increases. The mononuclear cell-containing fraction is conveyed to the source from the separator at the procedure setpoint. The blood draw and separation are then ended.
-
-
-
-
-
-
-
-
-